Veterinus Derma GeL®'s development case - using the most sophisticated techniques - has been internationally rewarded by Harvard Business School and Euromanagement, during their First International Conference held in Paris on October 30 & 31, 1997. During that conference, some of the innovative techniques and assessment methods specifically developed for Veterinus Derma GeL® on a 3-dimensional reconstructed skin model were divulged.

This type of model has been used to evaluate the transcutaneous passage of pharmaceutical molecules (Coquette et al., 1996) in the immunological response of the skin (Reins et al., 1994) and to evaluate the irritant / sensitizing effect. Comparing the results of these studies with those obtained during « in vivo» studies reveals close correlations (Slivka and Zeigler et al., 1993).

To evaluate its efficacy, Veterinus Derma GeL® has undergone extensive scientific research and numerous stringent comparative testing performed on a 3-dimensional reconstructed skin models to assess cell viability and the quantification of TNFa , IL-1a , IL-10, IL-8, IL-12 and PGE2.

Furthermore, Veterinus Derma GeL® has been tested according to OECD guideline nr. 471, on strains originating from the Laboratory of Prof. B. AMES, California University, USA, establishing that Veterinus Derma GeL® is non-mutagenic. Moreover, this absence of alteration or mutation of epithelial cells ensures a healthy and rapid healing process without proud flesh and hair discoloration at regrowth..